Abstract 9516: Chronic and Continuous Use of Adaptive Servo-Ventilation Improves and Keeps Cardiac Function in Patient With Heart Failure With Central Sleep Apnea
Central sleep apnea (CSA) is closely associated with poor prognosis in heart failure (HF) patient. Adaptive servo-ventilation (ASV) is a new treatment for HF with CSA patient. However, there is little evidence in chronic use.
We examined 70 HF with CSA patients treated with ASV seen between May 2008 and November 2012 in our hospital, retrospectively, who had not been admitted to the hospital due to worsening HF in the 6 months before initiating ASV therapy. We divided it into 2 groups: (A) non-continues-ASV-treated patients; (B) continues-ASV-treated patients. 18 patients (group A) used ASV only in the hospital and could not continue because of its discomfort. 52 patients (group B) could continue to night time use the ASV device after leaving the hospital. The median follow up time was 364 days after leaving hospital. There were almost no significant differences in the baseline characteristics between two groups. In group B, during 6, 12, 24 months observation, left ventricular ejection fraction (45.5 +/- 18.6 to 48.2 +/- 17.1, 41.5 +/- 18.7, and 47.8 +/- 18.1%, p<0.05 compared with baseline) and brain natriuretic peptide (752.0 +/- 1166.1 to 253.8 +/- 392.0, 455.3 +/- 1029.1 and 192.7 +/- 212.3 pg/ml, p<0.05 compared with baseline) improved significantly. And there was significantly less, than group A, by cardiac death (11.1% vs. 7.8%, p<0.05) and by readmission by worsening HF (55.6% vs. 19.2%, p<0.05).
This study showed that continues ASV therapy improved and kept the cardiac function, and that might improve prognosis of HF with CSA patients than short time use.
Author Disclosures: T. Ikeda: None. M. Fujimoto: None. K. Okeie: None. M. Yamamoto: None. H. Murai: None. S. Usui: None. M. Takamura: None. S. Kaneko: None.
- © 2014 by American Heart Association, Inc.